Article information
Fundamento
Estudiar la sensibilidad a antifúngicos de las levaduras patógenas emergentes para conocer su posible resistencia ante la necesidad de aplicar un tratamiento
Material y métodosSe investiga la sensibilidad in vitro de 69 cepas de levaduras aisladas de muestras clínicas, pertenecientes a 24 especies diferentes, frente a anfotericina B, fluconazol, itraconazol, ketoconazol y 5-fluorocitosina, utilizando el método Sensititre YeastOne.®
ResultadosSolamente 9 especies se mostraron sensibles a todos los antifúngicos: Candida famata, C. guillermondii, C. holmii, C. kefyr, C. pelliculosa, C. rugosa, C. utilis, C. zeylanoides y Trichosporon cutaneum; las demás presentaron resistencia a algún antifúngico. C. haemulonii, Pichia farinosa y Trichosporon mucoides, fueron resistentes a anfotericina B; C. haemulonii, C. inconspicua, C. lusitaniae, C. norvegensis, C. pintolepesii, C. valida, P. ohmeri, Rhodotorula glutinis, R. minuta, R. mucilaginosa y Saccharomyces cerevisiae fueron resistentes a derivados azólicos; Blastoschizomyces capitatus y C. lipolytica fueron resistentes a 5-fluorocitosina
ConclusionesLa resistencia de las levaduras patógenas emergentes a anfotericina B y 5-fluorocitosina es escasa, mientras que para los azoles es bastante significativa, especialmente al fluconazol (36%). Muchas de estas levaduras plantean problemas de resistencia intrínseca. En las infecciones por levaduras, es importante la correcta identificación de las especies y el estudio de sensibilidad in vitro para elegir el tratamiento antifúngico más adecuado
Palabras clave:
levaduras
antifúngicos
Candida
fluconazol
Background
To study the antifungal susceptibility of emerging yeast pathogens to know their possible resistance under the need of applying a treatment
Material and methodsWe investigated the in vitro susceptibility of 69 yeast strains isolates of clinical samples, belonging to 24 different species, to amphotericin B, fluconazole, itraconazole, ketoconazole and 5-fluorocytosine
ResultsOnly 9 species showed susceptibility to all antifungal agents: Candida famata, C. guillermondii, C. holmii, C. kefyr, C. pelliculosa, C. rugosa, C. utilis, C. zeylanoides y Trichosporon cutaneum; the rest of them presented resistance to some antifungal agent. C. haemulonii, Pichia farinosa and Trichosporon mucoides were resistant to amphotericin B; C. haemulonii, C. inconspicua, C. lusitaniae, C. norvegensis, C. pintolepesii, C. valida, P. ohmeri, Rhodotorula glutinis, R. minuta, R. mucilaginosa and Saccharomyces cerevisiae were resistant to azoles; Blastoschizomyces capitatus and C. lipolytica were resistant to 5-fluorocytosine
ConclusionsThe resistance of emerging yeast pathogens to amphotericin B and 5-fluorocytosine is low, while resistance to azoles is significative, especially to fluconazole (36%). Many of this yeasts present problems of intrinsic resistance. In yeast infections, the correct identification of species and the study of the in vitro susceptibility is important in order to choose the most adequate antifungal treatment
Key words:
Yeasts
antifungal agents
Candida
fluconazole
Full text is only aviable in PDF
Bibliografía
[1.]
J.R. Wingard.
Importance of Candida species other than C. albicans as pathogens in oncology patients.
Clin Infect Dis, 20 (1995), pp. 115-125
[2.]
S.E. Vartivarian, E.J. Anaissie, G.P. Bodey.
Emerging fungal pathogens in immunocompromised patients: clasification, diagnosis and management.
Clin Infect Dis, 17 (1993), pp. 5487-5491
[4.]
D.C. Coleman, M.G. Rinaldei, K.A. Havnes, J.H. Rex, R.C. Summerbell, E.J. Anaissie, et al.
Importance of Candida species other than Candida albicans as opportunistic pathogens.
Med Mycol, 36 (1998), pp. 156-165
[5.]
W.G. Merz.
Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance.
J Clin Microbiol, 20 (1984), pp. 1194-1195
[6.]
J.F. Ryley, R.G. Wilson, K.J. Barrett-Bee.
Azole resistance in Candida albicans.
J Med Vet Mycol, 22 (1984), pp. 53-63
[7.]
W.G. Powderly, G.S. Kobayashi, G.P. Herzig, G. Medoff.
Amphothericin B-resistant yeast infection in severely immunocompromised patients.
Am J Med, 84 (1988), pp. 826-832
[8.]
D.W. Warnock, J. Burke, N.J. Cope, E.M. Johnson, N.A. von Fraunhofer, E.W. Williams.
Fluconazole resistance in Candida glabrata.
Lancet, 2 (1988), pp. 1.310
[9.]
J. Dupouy-Camet, A. Paugam, C. De Donato, C. Viguie, I. Vicens, P.J. Volle, et al.
Résistance au fluconazole en milieu hospitalier. Concordance entre la résistance de Candida albicans in vitro et l’échec thérapeutique.
Presse Med, 20 (1991), pp. 1341
[10.]
B.L. Roder, C. Sonnenschein, S.H. Hartzen.
Failure of fluconazole therapy in Candida krusei fungemia.
Eur J Clin Microbiol Infect Dis, 10 (1991), pp. 173
[11.]
V.S. Kitchen, M. Savage, J.R. Harris.
Candida albicans resistance in AIDS.
J Infect, 22 (1991), pp. 204-205
[12.]
M.P. Dube, P.N. Heseltine, M.G. Rinaldi, S. Evans, B. Zawacki.
Fungemia and colonization with nystatin-resistant Candida rugosa in a burn unit.
Clin Infect Dis, 18 (1994), pp. 77-82
[13.]
P. Sandven, K. Nilsen, A. Digranes, T. Tjade, J. Lassen.
Candida norvegensis: fluconazole-resistant species.
Antimicrob Agents Chemother, 41 (1997), pp. 1.375-1.376
[14.]
National Committee for Clinical Laboratory Standards.
Reference method for broth dilution antifungal susceptibility testing of yeasts, M27-A., National Committee for Clinical Laboratory Standars, (1997),
[15.]
W.K. To, A.W. Fothergill, M.G. Rinaldi.
Comparative evaluation of macrodilution and Alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolates.
J Clin Microbiol, 33 (1995), pp. 2.660-2.664
[16.]
S. Arikan, D. Gur, M. Akova.
Comparison of E-test, microdilution and colorimetric dilution with reference broth macrodilution method for antifungal susceptibility testing of clinical significant Candida species isolated from immunocompromised patients.
Mycoses, 40 (1997), pp. 291-296
[17.]
M.A. Pfaller, S.A. Messer, R.J. Hollis, A. Espinel-Ingroff, M.A. Ghannoum, H. Plavan, et al.
Multisite reproductibility of MIC by Sensititre YeastOne colorimetric antifungal susceptibility panel.
Diagn Microbiol Infect Dis, 31 (1998), pp. 543-547
[18.]
A. Espinel-Ingroff, M. Pfaller, S.A. Messer, C.C. Knapp, S. Killian, H.A. Norris, et al.
Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the National Commitee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.
J Clin Microbiol, 37 (1999), pp. 591-595
[19.]
J.M. Torres-Rodríguez, N. Madrenys, T. Jiménez, P. Saballs.
Concentraciones mínimas inhibitorias de levaduras a cinco antifúngicos utilizando un micrométodo de dilución estandarizado y E-test.
Rev Iberoam Micol, 14 (1997), pp. 115-118
[20.]
M.J. Linares, J.F. Muñoz, F. Solis, F.C. Rodríguez, A. Valero, M. Casal.
Study of susceptibility of yeast isolates of clinical interest to five antifungal agents using the E-test.
Rev Esp Quimioterapia, 11 (1998), pp. 64-69
[21.]
A.J. Carrillo-Muñoz, G. Quindós, I. Gasser, C. Tur-Tur, M.T. Ruesga, R. Alonso-Vargas, et al.
Determinación mediante el sistema Sensititre de la sensibilidad in vitro a los antifúngicos de levaduras de interés médico.
Rev Esp Quimioterapia, 12 (1999), pp. 126-135
[22.]
J.H. Rex, M.A. Pfaller, J.N. Galgiani, M.S. Barlett, A. Espinel-Ingroff, M.A. Ghannoum, et al.
Development of interpretative breakpoints for antifungal susceptibility testing: Conceptual framework and analysis in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infection.
Clin Infect Dis, 24 (1997), pp. 235-247
[23.]
C. Girmenia, A. Micozi, M. Venditti, G. Meloni, A.P. Iori, S. Bastianello, et al.
Fluconazole treatment of Blastoschizomyces capitatus meningitis in an allo bone marrow recipient.
Eur J Clin Microbiol Infect Dis, 10 (1991), pp. 752-756
[24.]
I. Polacheck, I.F. Salkin, R. Kitzes-Cohen, R. Raz.
Endocarditis caused by Blastoschizomyces capitatus and taxonomic review genus.
J Clin Microbiol, 30 (1992), pp. 2.318-2.322
[25.]
D. D´Antonio, R. Piccolomini, G. Fioritoni, A. Iacome, S. Betti, P. Fazzi, et al.
Osteomyelitis and invertebral discitis caused by Blastoschizomyces capitatus a patient with acute leukemia.
J Clin Microbiol, 32 (1994), pp. 224-247
[26.]
M.A. Sanz, F. López, M.L. Martínez, G.F. Sanz, J.A. Martínez, G. Martín, et al.
Disseminated Blastoschizomyces capitatus infection in acute myeloblastic leukaemia. Report of three cases.
Support Care Cancer, 4 (1996), pp. 291-293
[27.]
A.M. Ortiz, C. Sanz-Rodríguez, J. Culebras, B. Buendía, I. González-Alvaro, E. Ocón, et al.
Multiple spondylodiscitis caused by Blastoschizomyces capitatus in an allo bone marrow transplantation recipient.
J Rheumatol, 25 (1998), pp. 2.276-2.278
[28.]
S. Krcmery, M. Dubrava, V. Krcmery.
Fungal urinary tract infections in patient at risk.
Int J Antimicrob Agents, 11 (1999), pp. 289-291
[29.]
M.Y. Cheung, N.C. Chiu, S.H. Chen, H.C. Liu, C.T. Ou, D.C. Liang.
Mandibular osteomyelitis caused by Blastoschizomyces capitatus in a child acute myelogenous leukemia.
J Formos Med Assoc, 98 (1999), pp. 787-789
[30.]
I. Pérez-Sánchez, J. Anguita, P. Martín-Rabadán, P. Muñoz, D. Serrano, A. Escudero, et al.
Blastoschizomyces capitatus infection in acute leukemia patients.
Leuk Lymphoma, 39 (2000), pp. 209-212
[31.]
N.A. Rao, A.V. Nerenberg, D.J. Forster.
Torulopsis Candida (Candida famata) endophthalmitis simulating Propionibacterium acnes syndrome.
Arch Ophthalmol, 109 (1991), pp. 1.718-1.721
[32.]
G. Quindós, F. Cabrera, M.C. Arilla, A. Burgos, R. Ortiz-Vingon, J.L. Canon, et al.
Fatal Candida famata peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis who was treated with fluconazole.
Clin Infect Dis, 18 (1994), pp. 658-660
[33.]
G. Carrega, G. Riccio, L. Santoriello, M. Pasqualini, R. Pellicci.
Candida famata fungemia in a surgical patient successfully treated with fluconazole.
Eur J Clin Microbiol Infect Dis, 16 (1997), pp. 698-699
[34.]
V. Krcmery, A. Kunova.
Candida famata fungemia in a cancer patient: case report.
J Chemother, 12 (2000), pp. 189-190
[35.]
J.A. Vázquez, T. Lundstrom, L. Dembry, P. Chandrasekar, D. Boikov, M.B. Parri, et al.
Invasive Candida guillermondii infection: in vitro susceptibility studies and molecular analysis.
Bone Marrow Transplant, 16 (1995), pp. 849-853
[36.]
D.J. Ainbinder, V.C. Parmley, T.H. Mader, M.L. Nelson.
Infectious crystalline keratopathy caused by Candida guillermondii.
Am J Ophthalmol, 125 (1998), pp. 723-725
[37.]
H.J. Tietz, V. Czaika, W. Sterry.
Case report. Osteomyelitis caused by high resistant Candida guillermondii.
Mycoses, 42 (1999), pp. 577-580
[38.]
M. Mardani, H.A Hanna, E. Girgawy, I. Raad.
Nosocomial Candida guillermondii fungemia in cancer patients.
Infect Control Hosp Epidemiol, 21 (2000), pp. 336-337
[39.]
I.B. Gargeya, W.R. Pruitt, S.A. Meyer, D.G. Ahearn.
Candida haemulonii from clinical specimens in the USA.
J Med Vet Mycol, 29 (1991), pp. 335-338
[40.]
C.B. Murdock, J.F. Fisher, D. Loebl, W.H. Chew.
Osteomyelitis of the hand due Toluropsis holmii.
South Med J, 76 (1983), pp. 1.460-1.461
[41.]
G.G. Baily, C.B. Moore, S.M. Essayag, S. de Wit, J.P. Burnie, D.W. Denning.
Candida inconspicua, a fluconazol-resistant pathogen in patients infected with human immunodeficiency virus.
Clin Infect Dis, 25 (1997), pp. 161-163
[42.]
D. D´Antonio, B. Violante, A. Mazzoni, T. Bonfini, M.A. Capuani, F. Daloia, et al.
A nosocomial cluster of Candida inconspicua infections in patients with hematological malignancies.
J Clin Microbiol, 36 (1998), pp. 792-795
[43.]
M.A. Morgan, C.J. Wilkowske, G.D. Roberts.
Candida pseudotropicalis fungemia and invasive disease in an immunocompromised patient.
J Clin Microbiol, 20 (1984), pp. 1.006-1.007
[44.]
H. Listemann, K.D. Schulz, R. Wasmuth, F. Begemann, W. Meigel.
Oesophagitis caused by Candida kefyr.
Mycoses, 41 (1998), pp. 3.434-3.444
[45.]
C. Farina, F. Cailiti, A. Manisco, A. Goglio.
Fuangaemia survey: a 10-year experience in Bergamo, Italy.
Mycoses, 42 (1999), pp. 543-548
[46.]
V. Nitzulesco, M. Niculescu.
Three cases of ocular candidiasis caused by Candida lipolytica.
Arch Roum Pathol Exp Microbiol, 35 (1976), pp. 269-272
[47.]
P. García-Martos, F. de la Rubia, M.J. Palomo, M.M. Álvarez, P. Marín, J. Mira.
Candida lipolytica, un nuevo patógeno oportunista.
Enferm Infecc Microbiol Clin, 11 (1993), pp. 163-164
[48.]
R. Guinet, J. Chanas, A. Goullier, G. Bonnefoy, P. Ambroise-Thomas.
Fatal septicemia due to amphotericin B-resistant Candida lusitaniae.
J Clin Microbiol, 18 (1983), pp. 443-444
[49.]
J.G. Baker, H.L. Nadler, P. Forgacs, S.R. Kurtz.
Candida lusitaniae: a new opportunistic pathogen of the urinary tract.
Diagn Microbiol Infect Dis, 2 (1984), pp. 145-149
[50.]
P.J. Sánchez, B.H. Cooper.
Candida lusitaniae: sepsis and meningitis in a neonate.
Pediatr Infect Dis J, 6 (1987), pp. 758-759
[51.]
P. García-Martos, J. Díaz, M. Castaño, M. Pérez, P. Marín.
Peritonitis caused by Candida lusitaniae in patient on continuous ambulatory peritoneal dialysis (CAPD.
Clin Nephrol, 36 (1991), pp. 50-51
[52.]
H. Nielsen, J. Stenderup, B. Bruun, J. Ladefoged.
Candida norvegensis peritonitis and invasive disease in a patient on continuous ambulatory peritoneal dialysis.
J Clin Microbiol, 28 (1990), pp. 1.664-1.665
[53.]
S.V. Hood, C.B. Moore, D.W. Denning.
Isolation of Candida norvegensis from clinical specimens: four case reports.
Clin Infect Dis, 23 (1996), pp. 1.185-1.187
[54.]
H. Nielsen, J. Stenderup.
Invasive Candida norvegensis infection in immunocompromised patients.
Scand J Infect Dis, 28 (1996), pp. 311-312
[55.]
A.S. Klein, G.T. Tortora, R. Malowitz, W.H. Greene.
Hansenula anomala: a new fungal pathogen.
Arch Intern Med, 148 (1988), pp. 1210-1213
[56.]
F. López, G. Martín, M.L. Paz, M.A. Danz.
Hansenula anomala en fungemia aguda.
Enferm Infecc Microbiol Clin, 8 (1990), pp. 363-364
[57.]
R. Salesa, A. Burgos, C. Fernández-Mazarrasa, G. Quindós, J. Pontón.
Transient fungaemia due to Candida pelliculosa in a patient with AIDS.
Mycoses, 34 (1991), pp. 327-329
[58.]
A. Moses, S. Maayan, Y. Shvil, A. Dudin, I. Ariel, A. Thalji, et al.
Hansenula anomala intections in children: from asymptomatic colonization to tissue invasion.
Pediatr Infect Dis J, 10 (1991), pp. 400-402
[59.]
S. Hirasaki, T. Ijichi, N. Fujita, S. Araki, H. Gotoh, M. Nakagawa.
Fungemia caused by Hansenula anomala: sucessful treatment with fluconazole.
Intern Med, 31 (1992), pp. 622-624
[60.]
E.S. Arisoy, A. Correa, D.K. Seilheimer, S.L. Kaplan.
Candida rugosa central catheter infection in a child.
Pediatr Infect Dis J, 12 (1993), pp. 961-963
[61.]
S. Shenoy, M. Samuga, S. Urs, K.M. Anuradha, M.M. Kurian, A. Augustine, et al.
Intravenous catheter-related Candida rugosa fungaemia.
Trop Doct, 26 (1996), pp. 31-32
[62.]
A. Alsina, M. Mason, R.A. Uphoff, W.S. Riggsby, J.M. Becker, D. Murphy.
Catheter-associated Candida utilis fungemia in a patient with acquired immunodeficiency syndrome: species verification with a molecular probe.
J Clin Microbiol, 26 (1988), pp. 621-624
[63.]
M.E. Bougnoux, E. Gueho, A.C. Potocka.
Resolutive Candida utilis fungemia in a non neutropenic patient.
J Clin Microbiol, 31 (1993), pp. 1.644-1.645
[64.]
M.H. Shih, M.M. Sheu, H.Y. Chen, S.R. Lin.
Fungal keratitis caused by Candida utilis case report.
Kao Hsiung I Hsueh Ko Hsueh Tsa Chih, 15 (1999), pp. 171-174
[65.]
K.C. Hazen, G.W. Theisz, S.A. Howell.
Chronic urinary tract infection due to Candida utilis.
J Clin Microbiol, 37 (1999), pp. 824-827
[66.]
D. Levenson, M.A. Pfaller, M.A. Smith, R. Hollis, T. Gerarden, C.B. Tucci.
Candida zeylanoides: another opportunistic yeast.
J Clin Microbiol, 29 (1991), pp. 1.689-1.692
[67.]
J. Bisbe, J. Vilardell, M. Valls, A. Moreno, M. Brancos, J. Andreu.
Transient Candida fungemia and arthritis due to Candida zeylanoides.
Eur J Clin Microbiol Infect Dis, 6 (1987), pp. 668-669
[68.]
C.R. Paula, M.C. Sampaio, E.G. Birman, A.M. Siqueira.
Oral yeast in patients with cancer of the mouth, before and during radiotherapy.
Mycopathologia, 112 (1990), pp. 119-124
[69.]
M.M. Bergman, D. Gagnon, G.V. Doern.
Pichia ohmeri fungemia.
Diagn Microbiol Infect Dis, 30 (1998), pp. 229-231
[70.]
B.Y Choy, S.S Wong, T.M. Chan, K.N. Lai.
Pichia ohmeri peritonitis in a patient on CAPD: response to treatment with amphotericin.
Perit Dial Int, 20 (2000), pp. 91-92
[71.]
Y. Naveh, A. Friedman, D. Merzbach, N. Hashman.
Endocarditis caused by Rhodotorula sucessfully treated with 5-fluorocytosine.
Br Heart J, 37 (1975), pp. 100-104
[72.]
R.S. Pore, J. Chen.
Meningitis caused by Rhodotorula.
Sabouradia, 14 (1976), pp. 331-335
[73.]
V. Wrong, L. Ross, L. Opas, E. Lieberman.
Rhodotorula rubra peritonitis in a child undergoing intermittent cycling peritoneal dialysis.
J Infect Dis, 157 (1988), pp. 393-394
[74.]
E. Kiehn, E. Gorey, A.E. Brown, F.F. Edwards, D. Armstrong.
Sepsis due to Rhodotorula related to use of indwelling central venous catheters.
Clin Infect Dis, 14 (1992), pp. 841-846
[75.]
M.E. Jiménez-Mejías, C. Ortiz, F.J. Jiménez-Gonzalo, M. del Nozal, T. Campos, F.J. Jiménez.
Fungemia por Rhodotorula mucilaginosa en relación con nutrición parenteral total.
Enferm Infecc Microbiol Clin, 10 (1992), pp. 543-546
[76.]
J.K. Gregory, J.A. Haller.
Chronic postoperative Rhodotorula endophtalmitis.
Arch Ophthalmol, 110 (1992), pp. 1.686-1.687
[77.]
S.H. Dougherty, L. Simmons.
Postoperative peritonitis caused by Saccharomyces cerevisiae.
Arch Surg, 117 (1982), pp. 248-249
[78.]
N. Cimolai, M.J. Gill, D. Church.
Saccharomyces cerevisiae fungemia: case report and review of the literature.
Diagn Microbiol Infect Dis, 8 (1987), pp. 113-117
[79.]
O.W. Tawfik, C.J. Papasian, A.Y. Dixon, L.M. Potter.
Saccharomyces cerevisiae pneumonia in a patient with acquired immunodeficiency syndrome.
J Clin Microbiol, 27 (1989), pp. 1.689-1.691
[80.]
M.G. Doyle, L.K. Pickering, N. O’Brien, K. Hoots, J.E. Benson.
Saccharomyces cerevisiae infection in a patient with acquired inmunodeficiency syndrome.
Pediatr Infect Dis J, 9 (1990), pp. 850-851
[81.]
J.N. Aucott, J. Fayen, H. Grossnicklas, A. Morrisey, M.M. Lederman, R.A. Salata.
Invasive infection with Saccharomyces cerevisiae: report of three cases and review.
Rev Infect Dis, 12 (1990), pp. 406-411
[82.]
G.M. Chertow, E.R. Marcantonio, R.G. Wells.
Saccharomyces cerevisiae empyema in a patient with esophago-pleural fistula complicating variceal sclerotherapy.
Chest, 99 (1991), pp. 1.518-1.519
[83.]
J.D. Sobel, J. Vázquez, M. Lynch, C. Meriwether, M.J. Zervos.
Vaginitis due to Saccharomyces cerevisiae: Epidemiology, clinical aspects, and therapy.
Clin Infect Dis, 16 (1993), pp. 93-99
[84.]
D.M. Walling, D.J. McGraw, W.G. Merz, J.E. Karp, G.M. Hutchins.
Disseminated infection with Trichosporon beigelii.
Rev Infect Dis, 9 (1987), pp. 1.013-1.019
[85.]
T.J. Walsh, G.P. Melcher, M.C. Rinaldi, J. Lecciones, D.A. McGough, P. Kelly, et al.
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B.
J Clin Microbiol, 28 (1990), pp. 1.616-1.622
[86.]
M.G. Sidarous, M.V. O’Reilly, C.E. Cherubin.
A case of Trichosporon beigelii endocarditis 8 years after aortic valve replacement.
Infect Dis Newsletter, 11 (1992), pp. 60-61
[87.]
P. García-Martos, J. Mira-Gutiérrez.
Trichosporon y tricosporonosis: a propósito de 13 casos.
Rev Iberoam Micol, 12 (1995), pp. 111-113
[88.]
K.G. Davey, A. Szekely, E.M. Johnson, D.W. Warnock.
Comparison of a new commercial colorimetric microdilution method with a standard method for in vitro susceptibility testing of Candida spp. and Cryptococcus neoformans.
J Antimicrob Chemother, 42 (1998), pp. 439-444
[89.]
J.M. Torres-Rodríguez, M. Sabaté, C. Gallach, A. Carrillo, N. Madrenys.
Sensibilidad in vitro a la 5-fluorocitosina y anfotericina B de levaduras del género Candida aisladas en Barcelona.
Enferm Infecc Microbiol Clin, 8 (1990), pp. 91-93
[90.]
A. Carceller, J.M. Torres-Rodríguez, M.C. Nicolás, N. Madrenys.
Sensibilidad de 210 cepas de Candida sp. a 6 antifúngicos utilizando un medio sólido en microplaca.
Rev Iberoam Micol, 8 (1991), pp. 70-74
[91.]
P. Arévalo, A. Arias, A. Anfreu, A. Sierra.
Sensibilidad de 278 aislados de Candida albicans frente a anfotericina B, fluconazol e itraconazol.
Rev Iberoam Micol, 9 (1992), pp. 94-96
[92.]
A. Burgos, J. Bikandi, M. Fernández-Rodríguez, J. Pontón, R. Cisterna, G. Quindós.
Correlación entre los serotipos A y B de Candida albicans y su sensibilidad a anfotericina B y 5-fuorocitosina.
Rev Esp Quimioterapia, 5 (1992), pp. 79-85
[93.]
D.J. Drutz, R.I. Lehrer.
Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function.
Am J Med Sci, 276 (1978), pp. 77-92
[94.]
S.M. Seidenfeld, B.H. Cooper, J.W. Smith, J.P. Luby, P.A. Mackowiak.
Amphotericin B tolerance: a characteristic of Candida parapsilosis not shared by other Candida species.
J Infect Dis, 147 (1983), pp. 116-119
[95.]
W.G. Merz.
Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance.
J Clin Microbiol, 20 (1984), pp. 1.194-1.195
[96.]
J.D. Dick, B.R. Rosengard, W.G. Merz, R.K. Stuart, G.M. Hutchins, R. Saral.
Fatal disseminated candidiasis due to amphotericin B-resistant Candida guilliermondii.
Ann Intern Med, 102 (1985), pp. 67-68
[97.]
W.G. Merz, J.E. Karp, D. Schron, R. Saral.
Increased incidence of fungemia caused by Candida krusei.
J Clin Microbiol, 24 (1986), pp. 581-584
[98.]
E.A. Bryce, F.J. Roberts, A.S. Sekhon, A.J. Coldman.
Yeast in blood cultures. Evaluation of factors influencing outcome.
Diagn Microbiol Infect Dis, 15 (1992), pp. 233-237
[99.]
T.R. Sterling, R.B. Gasser, A. Ziegler.
Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host.
Clin Infect Dis, 23 (1996), pp. 187-188
[100.]
M. Lozano-Chiu, M.U. Lancaster, J.H. Rex.
Evaluation of a colorimetric method for detecting amphotericin B-resistant Candida isolates.
Diagn Microbiol Infect Dis, 31 (1998), pp. 417-424
[101.]
J.R. Wingard, W.G. Merz, M.G. Rinaldi, T.R. Johnson, J.E. Karp, R. Saral.
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.
N Engl J Med, 325 (1991), pp. 1.274-1.277
[102.]
R. Fox, K.R. Neal, C.L. Leen, M.E. Ellis, B.K. Mandal.
Fluconazole resistant Candida in AIDS.
J Infect, 22 (1991), pp. 201-204
[103.]
J.H. Rex, M.G. Rinaldi, M.A. Pfaller.
Resistance of Candida species to fluconazole.
Antimicrob Agents Chemother, 39 (1995), pp. 1-8
[104.]
F. Barchiesi, A.L Colombo, D.A McGrough, A.W Fothergill, M.G. Rinaldi.
In vitro activity of itraconazole against fluconazole-susceptible and resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.
Antimicrob Agents Chemother, 38 (1994), pp. 1.530-1.533
[105.]
J.V. Martínez-Suárez, J.L. Rodríguez-Tudela.
Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain.
Antimicrob Agents Chemother, 39 (1995), pp. 1.512-1.516
[106.]
F. Galán-Sánchez, P. García-Martos, C. Rodríguez-Ramos, P. Marín-Casanova, J. Mira-Gutiérrez.
Microbiological characteristics and susceptibility patterns of strains of Rhodotorula isolated from clinical samples.
Mycopathologia, 145 (1999), pp. 109-112
[107.]
D. Arzeni, M. Del Poeta, O. Simonetti, A.M. Offidami, L. Lamura, M. Balducci, et al.
Prevalence and antifungal susceptibility of vaginal yeasts in patients attending a gynecological center in Ancona, Italy.
Eur J Epidemiol, 13 (1997), pp. 447-450
[108.]
D. D´Antonio, A. Mazzoni, A. Iacome, B. Violante, M.A. Capuani, F. Schioppa, et al.
Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients.
J Clin Microbiol, 34 (1996), pp. 753-755
[109.]
T.J. Walsh, M.A. Viviani, E. Arathoon, C. Chiou, M. Ghannoum, A.H. Groll, et al.
New targets and delivery sustems for antifungal therapy.
Med Mycol, 38 (Suppl 1 (2000), pp. 335-347
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
